Infliximab for Immune Checkpoint Inhibitor Associated AKI

Summary

This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone 1mg/kg/day x 2 weeks followed by a 4 week taper) on the rate and speed of renal recovery from immune checkpoint inhibitor-associated AKI.

Timeline

Start

2026-07-16

Primary completion

2029-01-15

Completion

2029-07-16

Drugs

Indications